English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 

Overview
Pipeline
Collaborations
Commercialisation
Team
History
Facility

 Research Collaborations and Licensing Agreements

Contact

Dr Thomas Borcholte, Chief Business Officer

Tel.: +49 (0)89 - 41 31 38 - 0
E-Mail: licensing@wilex.com

Major Active Collaborations, Strategic Alliances and Licensing Agreements

WILEX collaborates and has license agreements with a number of leading academic and clinical institutions as well as pharmaceutical companies in Europe and North America. The Company considers these relationships to be important to its ability to gain access to and exploit possible new developments within its business focus.

Collaborating Partner Area of Collaborations Read more  
UCB Pharma S.A., Brussels, Belgium UCB and WILEX to enter into strategic alliance to develop UCB's preclinical oncology portfolio
Press Release
Bayer Corporation, Tarrytown, NY, USA Licensing agreement on MN/CA IX antigen of the RENCAREX® antibody Press Release
Centocor Inc., Malvern, USA/University of Leiden, Netherlands Licensing of G250/RENCAREX® antibody Press releases
Ludwig Institute for Cancer Research, New York, USA Clinical Phase I and II trials with WX-G250 antibody and 124Iodine-G250 in the US Press release
Fox Chase Cancer Center, Philadelphia, USA Collaboration to conduct clinical Phase I and II trials with WX-UK1 in combination with capecitabine. The studies are supported with a USD 5.0 million grant from the U.S. Department of Defense Breast Cancer Research Program Press release
Department of Urology of the David Geffen School of Medicine at UCLA, University of California, Los Angeles, USA Collaboration with a research group of Prof. Arie Belldegrun to examine the pre-clinical efficacy of the WX-G250 (RENCAREX®) antibody in mouse models  
Slovak Academy of Sciences, Bratislava, Slovakia

 Collaboration with a research group of Prof. Pastorek to examine the CAIX antigen and the mode of action of the WX-G250 (RENCAREX®) antibody in different models    
Erasmus Medical Center, Rotterdam, Netherlands  Research collaboration on pre-clinical tests of WILEX’s drug candidates.   
 
Licence agreements are an important part of the Company’s commercialisation strategy. You will find details of existing partnerships or options for further cooperations here.
   
     
© 2006 WILEX AG